Skip to main content

Table 1 Baseline Characteristics

From: Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study

  

N=99

Sex

Male

77 (78%)

Female

22 (23%)

Age

 

73.2

BCVA (logMAR)

 

0.49 (0.43)

Medical history

Diabetes

20 (20%)

Hypertension

49 (50%)

Disease duration (years)

 

0.5 (±0.92)

Type of AMD

typical AMD

83 (84%)

PCV

13 (13%)

RAP

3 (3%)

FA classification

Predominantly classic

24 (24%)

Minimally classic

17 (17%)

Occult

58 (59%)

Past history

None

97 (98%)

Photocoagulation

1 (1%)

PDT

0 (0%)

Other anti-VEGF drugs

0 (0%)

Others

1 (1%)

  1. AMD age-related macular degeneration, BCVA best corrected visual acuity, logMAR logarithm of the minimal angle of resolution, PCV polypoidal choroidal vasculopathy, RAP retinal angiomatous proliferation, VEGF vascular endothelial growth factor